Jade Biosciences, Inc. Cash and Restricted Cash
Jade Biosciences, Inc. (JBIO) had Cash and Restricted Cash of $180.88 million as of 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2021-11-15
- 2021-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $180.88M.
- 2021-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $59.15M.
- 2020-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4.57M.
- 2020-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.46M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2021-09-30 | $180.88M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $59.15M 10-Q · filed 2021-08-16 |
| 2020-12-31 | $4.57M 10-Q · filed 2021-11-15 |
| 2020-09-30 | $7.46M 10-Q · filed 2021-11-15 |
| 2020-06-30 | $972.00K 10-Q · filed 2021-08-16 |
| 2019-12-31 | $3.51M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |